STADA Arzneimittel AG and Bio-Thera Solutions have partnered to develop and commercialize Gotenfia, a biosimilar to golimumab, aiming to enhance access to effective treatments for chronic inflammatory autoimmune diseases in Europe.

Target Company Overview

STADA Arzneimittel AG, based in Bad Vilbel, Germany, is a global leader in specialty pharmaceuticals and consumer healthcare. The company focuses on delivering high-quality generics, specialty medicines, and consumer healthcare products across over 100 countries. In the fiscal year 2024, STADA reported group sales amounting to €4,059 million and achieved an adjusted EBITDA of €886 million. With a workforce of around 11,649 employees worldwide, STADA is well-positioned in the healthcare industry.

Industry Overview in Germany

The pharmaceutical industry in Germany is one of the largest in Europe, accounting for a significant portion of the national economy. Driven by innovation, Germany is home to numerous research institutions and pharmaceutical companies dedicated to developing advanced therapeutic solutions. The annual revenue generated by the pharmaceutical sector alone is estimated to surpass €45 billion, making it a crucial element of the overall economy.

Furthermore, Germany’s regulatory environment supports pharmaceutical growth through stringent quality control and market access processes. The European Medicines